دورية أكاديمية
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic.
| العنوان: | Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic. |
|---|---|
| المؤلفون: | Solante R; San Lazaro Hospital, Manila, Philippines., Alvarez-Moreno C; Infectious Diseases Unit, Facultad de Medicina. Universidad Nacional de Colombia. Clinica Universitaria Colombia, Clínica Colsanitas, Colombia., Burhan E; Faculty of Medicine Universitas Indonesia, RSUP Persahabatan, Jakarta, Indonesia., Chariyalertsak S; Faculty of Public Health, Chiang Mai University, Chiang Mai, Thailand., Chiu NC; MacKay Memorial Hospital, Taipei, Taiwan., Chuenkitmongkol S; National Vaccine Institute, Nonthaburi Thailand., Dung DV; University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam., Hwang KP; China Medical University Children's Hospital, Taichung, Taiwan., Ortiz Ibarra J; Médico Hospital Materno Perinatal Monica Pretelini Sáez, Toluca de Lerdo, México., Kiertiburanakul S; Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand., Kulkarni PS; Serum Institute of India Pvt Ltd, Pune, India., Lee C; Taylor's School of Medicine, Petaling Jaya, Malaysia., Lee PI; Department of Pediatrics, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., Lobo RC; Philippine Children's Medical Center, Manila, Philippines., Macias A; Universidad de Guanajuato, Leon Gto, Mexico., Nghia CH; Institute Pasteur, Ho Chi Minh City, Vietnam., Ong-Lim AL; College of Medicine - Philippine General Hospital, University of the Philippines, Manila, Philippines., Rodriguez-Morales AJ; Faculty of Medicine, Fundacion Universitaria Autónoma de las Americas, Pereira, Risaralda, Colombia & Master of Clinical Epidemiology and Biostatistics, Universidad Cientifica del Sur, Lima, Peru., Richtmann R; Santa Joana Hospital and Maternity, the Institute of Infectious Diseases Emílio Ribas in Sao Paulo, Brazil., Safadi MAP; Santa Casa de Sao Paulo School of Medical Sciences, Sao Paulo, Brazil., Satari HI; Division of Infectious Diseases and Tropical Pediatrics, Department of Child Health Medical Faculty, Universitas Indonesia, Cipto Mangunkusumo Hospital, Indonesia., Thwaites G; Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam, and The Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK. |
| المصدر: | Expert review of vaccines [Expert Rev Vaccines] 2023 Jan-Dec; Vol. 22 (1), pp. 1-16. Date of Electronic Publication: 2022 Nov 11. |
| نوع المنشور: | Review; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101155475 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8395 (Electronic) Linking ISSN: 14760584 NLM ISO Abbreviation: Expert Rev Vaccines Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2015- : Abingdon, Oxford : Taylor & Francis Original Publication: London : Future Drugs Ltd., 2002- |
| مواضيع طبية MeSH: | COVID-19 Vaccines*/adverse effects , COVID-19*/epidemiology , COVID-19*/prevention & control, Humans ; Pandemics ; SARS-CoV-2 |
| مستخلص: | Introduction: COVID-19 vaccines have been highly effective in reducing morbidity and mortality during the pandemic. However, the emergence of the Omicron variant and subvariants as the globally dominant strains have raised doubts about the effectiveness of currently available vaccines and prompted debate about potential future vaccination strategies. Areas Covered: Using the publicly available IVAC VIEW-hub platform, we reviewed 52 studies on vaccine effectiveness (VE) after booster vaccinations. VE were reported for SARS-CoV-2 symptomatic infection, severe disease and death and stratified by vaccine schedule and age. In addition, a non-systematic literature review of safety was performed to identify single or multi-country studies investigating adverse event rates for at least two of the currently available COVID-19 vaccines. Expert Opinion: Booster shots of the current COVID-19 vaccines provide consistently high protection against Omicron-related severe disease and death. Additionally, this protection appears to be conserved for at least 3 months, with a small but significant waning after that. The positive risk-benefit ratio of these vaccines is well established, giving us confidence to administer additional doses as required. Future vaccination strategies will likely include a combination of schedules based on risk profile, as overly frequent boosting may be neither beneficial nor sustainable for the general population. |
| فهرسة مساهمة: | Keywords: AZD1222; COVID-19; CoronaVac; booster; mRNA; omicron; severe; vaccine effectiveness; waning immunity |
| المشرفين على المادة: | 0 (COVID-19 Vaccines) |
| SCR Protocol: | COVID-19 vaccine booster shot |
| SCR Organism: | SARS-CoV-2 variants |
| تواريخ الأحداث: | Date Created: 20221104 Date Completed: 20230119 Latest Revision: 20230210 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1080/14760584.2023.2143347 |
| PMID: | 36330971 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher 
Full Text Finder | تدمد: | 1744-8395 |
|---|---|
| DOI: | 10.1080/14760584.2023.2143347 |